Information de reference pour ce titreAccession Number: | 01451459-201111010-00020.
|
Author: | Cortese, Margaret M. 1; Barskey, Albert E. 1; Tegtmeier, Gary E. 3; Zhang, Cheryl 4; Ngo, Laurie 4; Kyaw, Moe H. 1,a; Baughman, Andrew L. 2; Menitove, Jay E. 3; Hickman, Carole J. 1; Bellini, William J. 1; Dayan, Gustavo H. 1,a; Hansen, Gail R. 5,a; Rubin, Steven 4
|
Institution: | (1)Division of Viral Diseases, National Center for Immunization and Respiratory Diseases (2)Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia (3)Community Blood Center of Greater Kansas City, Missouri (4)Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland (5)Kansas Department of Health and Environment, Topeka
|
Title: | |
Source: | Journal of Infectious Diseases. 204(9):1413-1422, November 01, 2011.
|
Abstract: | Background. In 2006, a mumps outbreak occurred on a university campus despite >= 95% coverage of students with 2 doses of measles-mumps-rubella (MMR) vaccine. Using plasma samples from a blood drive held on campus before identification of mumps cases, we compared vaccine-induced preoutbreak mumps antibody levels between individuals who developed mumps (case patients) and those who did not develop mumps (nonpatients).
Methods. Preoutbreak samples were available from 11 case patients, 22 nonpatients who reported mumps exposure but no mumps symptoms, and 103 nonpatients who reported no known exposure and no symptoms. Antibody titers were measured by plaque reduction neutralization assay using Jeryl Lynn vaccine virus and the outbreak virus Iowa-G/USA-06 and by enzyme immunoassay (EIA).
Results. Preoutbreak Jeryl Lynn virus neutralization titers were significantly lower among case patients than unexposed nonpatients (P = .023), and EIA results were significantly lower among case patients than exposed nonpatients (P = .007) and unexposed nonpatients (P = .009). Proportionately more case patients than exposed nonpatients had a preoutbreak anti-Jeryl Lynn titer < 31 (64% vs 27%, respectively; P = .065), an anti-Iowa-G/USA-06 titer < 8 (55% vs 14%; P = .033), and EIA index standard ratio < 1.40 (64% vs 9%; P = .002) and < 1.71 (73% vs 14%, P = .001).
Discussion. Case patients generally had lower preoutbreak mumps antibody levels than nonpatients. However, titers overlapped and no cutoff points separated all mumps case patients from all nonpatients.
(C) Copyright Oxford University Press 2011.
|
References: | 1. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States N Engl J Med. 2008;358:1580-9
2. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements Vaccine. 2009;27:6186-95
3. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 1998;47:1-57
4. Cortese MM, Jordan HT, Curns AT, et al. Mumps vaccine performance among university students during a mumps outbreak Clin Infect Dis. 2008;46:1172-80
5. Huang AS, Cortese MM, Curns AT, et al. Risk factors for mumps at a university with a large mumps outbreak Public Health Rep. 2009;124:419-26
6. Rubin SA, Qi L, Audet SA, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak J Infect Dis. 2008;198:508-15
7. Orvell C, Tecle T, Johansson B, Saito H, Samuelson A. Antigenic relationships between six genotypes of the small hydrophobic protein gene of mumps virus J Gen Virol. 2002;83:2489-96
8. Yates PJ, Afzal MA, Minor PD. Antigenic and genetic variation of the HN protein of mumps virus strains J Gen Virol. 1996;77:2491-7
9. Pipkin PA, Afzal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus J Virol Method. 1999;79:219-25
10. Cohen BJ, Audet S, Andrews N, Beeler JWHO working group on measles plaque reduction neutralization test. Vaccine. 2007;26:59-66
11. Bitsko RH, Cortese MM, Dayan GH, et al. Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage J Clin Microbiol. 2008;46:1101-3
12. Ennis FA. Immunity to mumps in an institutional epidemic. Correlation of insusceptibility to mumps with serum plaque neutralizing and hemagglutination-inhibiting antibodies J Infect Dis. 1969;119:654-7
13. Meyer MB, Stifler WC, Joseph JM. Evaluation of mumps vaccine given after exposure to mumps, with special reference to the exposed adult Pediatrics. 1966;37:304-15
14. Bashe WJ, Gotlieb T, Henle G, Henle W. Studies on the prevention of mumps. VI. The relationship of neutralizing antibodies to the determination of susceptibility and to the evaluation of immunization procedures J Immunol. 1953;71:76-85
15. Brunell PA, Brickman A, O'Hare D, Steinberg S. Ineffectiveness of isolation of patients as a method of preventing the spread of mumps. Failure of the mumps skin-test antigen to predict immune status N Engl J Med. 1968;279:1357-61
16. Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006 Vaccine. 2008;26:3601-7
17. Sosin DM, Cochi SL, Gunn RA, Jennings CE, Preblud SR. Changing epidemiology of mumps and its impact on university campuses Pediatrics. 1989;84:779-84
18. Henle G, Henle W, Wendell KK, Rosenberg P. Isolation of mumps virus from human beings with induced apparent or inapparent infections J Exp Med. 1948;88:223-32
19. Falk WA, Buchan A, Dow M, et al. The epidemiology of mumps in southern Alberta 1980-1982 Am J Epidemiol. 1989;130:736-49
20. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae Am J Epidemiol. 1975;101:532-51
|
Language: | English.
|
Document Type: | MAJOR ARTICLES AND BRIEF REPORTS.
|
ISSN: | 0022-1899
|
DOI Number: | https://dx.doi.org/10.1093/infdi...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|